A TWO PART SEAMLESS MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS.

Trial Profile

A TWO PART SEAMLESS MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs RG 7916 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUNFISH
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2017 According to a PTC Therapeutics media release, preliminary data from an early analysis of Part 1 of this trial were presented at CureSMA Conference.
    • 01 Jul 2017 Preliminary data from this trial published in a PTC Therapeutics Media Release.
    • 08 May 2017 According to a PTC Therapeutics media release, data from the first part of this study are expected to be presented at scientific meetings later this year (2017) and early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top